These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

77 related articles for article (PubMed ID: 9683844)

  • 21. [Evaluation of bevacizumab combined with irinotecan-based regimen as the first-line treatment for patients with metastatic colorectal cancer].
    Lin L; Xu JM; Wang Y; Ge FJ; Liu LJ; Zhao CH; Li SS; Liu JZ; Li ZQ
    Zhonghua Zhong Liu Za Zhi; 2010 Oct; 32(10):786-90. PubMed ID: 21163073
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Tumor marker CEA in monitoring of response to tegafur-uracil and folinic acid in patients with metastatic colorectal cancer.
    Wang WS; Lin JK; Lin TC; Chiou TJ; Liu JH; Yen CC; Chen WS; Jiang JK; Yang SH; Wang HS; Chen PM
    Hepatogastroenterology; 2002; 49(44):388-92. PubMed ID: 11995458
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical evaluation of CEA, CA19-9, CA72-4 and CA125 in gastric cancer patients with neoadjuvant chemotherapy.
    Sun Z; Zhang N
    World J Surg Oncol; 2014 Dec; 12():397. PubMed ID: 25543664
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Weekly irinotecan in patients with metastatic colorectal cancer failing 5-fluorouracil-based chemotherapy: efficacy and prognostic factors.
    Karaoğlu A; Yalcin S; Tekuzman G; Kars A; Celik I; Güler N; Ozişik Y; Türker A; Barişta I; Güllü I
    Tumori; 2003; 89(2):141-5. PubMed ID: 12841660
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Salvage chemotherapy with irinotecan, 5-fluorouracil and leucovorin for taxane- and cisplatin-refractory, metastatic gastric cancer.
    Kim ST; Kang WK; Kang JH; Park KW; Lee J; Lee SH; Park JO; Kim K; Kim WS; Jung CW; Park YS; Im YH; Park K
    Br J Cancer; 2005 May; 92(10):1850-4. PubMed ID: 15870718
    [TBL] [Abstract][Full Text] [Related]  

  • 26. CEA and CA19.9 as early predictors of progression in advanced/metastatic colorectal cancer patients receiving oxaliplatin-based chemotherapy and bevacizumab.
    Petrioli R; Licchetta A; Roviello G; Pascucci A; Francini E; Bargagli G; Conca R; Miano ST; Marzocca G; Francini G;
    Cancer Invest; 2012 Jan; 30(1):65-71. PubMed ID: 22236191
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Advanced pancreatic cancer successfully treated with continuous infusion of 5-fluorouracil and low-dose cisplatin.
    Kikuchi H; Ujiie S; Kanamaru R
    Intern Med; 1998 Jul; 37(7):635-7. PubMed ID: 9711896
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evaluating the efficacy of tumor markers CA 19-9 and CEA to predict operability and survival in pancreatic malignancies.
    Mehta J; Prabhu R; Eshpuniyani P; Kantharia C; Supe A
    Trop Gastroenterol; 2010; 31(3):190-4. PubMed ID: 21560524
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Diminishing impact of preoperative carcinoembryonic antigen (CEA) in prognosis of Dukes' C colorectal cancer.
    Katoh H; Yamashita K; Kokuba Y; Satoh T; Ozawa H; Hatate K; Ihara A; Nakamura T; Onozato W; Watanabe M
    Anticancer Res; 2008; 28(3B):1933-41. PubMed ID: 18630484
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Role of CA19.9 in predicting bevacizumab efficacy for metastatic colorectal cancer patients.
    Formica V; Massara MC; Portarena I; Fiaschetti V; Grenga I; Del Vecchio Blanco G; Sileri P; Tosetto L; Skoulidis F; Pallone F; Roselli M
    Cancer Biomark; 2009; 5(4):167-75. PubMed ID: 19729826
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Combined irinotecan and oxaliplatin in patients with advanced pre-treated pancreatic cancer.
    Cantore M; Rabbi C; Fiorentini G; Oliani C; Zamagni D; Iacono C; Mambrini A; Del Freo A; Manni A
    Oncology; 2004; 67(2):93-7. PubMed ID: 15539911
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A phase II study of irinotecan with 5-fluorouracil and leucovorin in patients with pretreated gastroenteropancreatic well-differentiated endocrine carcinomas.
    Ducreux MP; Boige V; Leboulleux S; Malka D; Kergoat P; Dromain C; Elias D; de Baere T; Sabourin JC; Duvillard P; Lasser P; Schlumberger M; Baudin E
    Oncology; 2006; 70(2):134-40. PubMed ID: 16645326
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [A case of fluoropyrimidine-resistant recurrent colon cancer successfully treated with weekly administration of irinotecan].
    Takashima T; Tayama Y; Nakamura Y; Hirata K
    Gan To Kagaku Ryoho; 2010 Apr; 37(4):719-21. PubMed ID: 20414034
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A phase II study of irinotecan alternated with a weekly schedule of high-dose leucovorin and 48-hour 5-fluorouracil infusion in patients with metastatic colorectal cancer.
    Rosati G; Rossi A; Reggiardo G; Manzione L
    Oncology; 2002; 62(3):209-15. PubMed ID: 12065867
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A randomized phase II trial of pemetrexed plus irinotecan (ALIRI) versus leucovorin-modulated 5-FU plus irinotecan (FOLFIRI) in first-line treatment of locally advanced or metastatic colorectal cancer.
    Underhill C; Goldstein D; Gorbounova VA; Biakhov MY; Bazin IS; Granov DA; Hossain AM; Blatter J; Kaiser C; Ma D
    Oncology; 2007; 73(1-2):9-20. PubMed ID: 18334829
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prognostic factors for disease-free survival after preoperative chemotherapy followed by curative resection in patients with colorectal cancer harboring hepatic metastasis: a single-institute, retrospective analysis in Asia.
    Yi JH; Kim H; Jung M; Shin SJ; Choi JS; Choi GH; Baik SH; Min BS; Kim NK; Ahn JB
    Oncology; 2013; 85(5):283-9. PubMed ID: 24217184
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Sequential carcinoembryonic antigen levels. A predictor of response and relapse in combination chemotherapy of advanced gastrointestinal cancer.
    Ichiki AT; Krauss S; Israelsen KL; Sonoda T; Collmann IR
    Oncology; 1981; 38(1):27-30. PubMed ID: 7443173
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A phase I/II study of irinotecan when added to 5-fluorouracil and leucovorin and pelvic radiation in locally advanced rectal cancer: a Colorectal Clinical Oncology Group Study.
    Glynne-Jones R; Falk S; Maughan TS; Meadows HM; Sebag-Montefiore D
    Br J Cancer; 2007 Feb; 96(4):551-8. PubMed ID: 17262086
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Usefulness of serial carcinoembryonic antigen (CEA) determinations in monitoring chemotherapy.
    Young VL; Kashmiri R; Hazen ZR; Meeker WR
    South Med J; 1976 Oct; 69(10):1274-6. PubMed ID: 982100
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The diagnostic importance of CEA and CA 19-9 for the early diagnosis of pancreatic carcinoma.
    Nazli O; Bozdag AD; Tansug T; Kir R; Kaymak E
    Hepatogastroenterology; 2000; 47(36):1750-2. PubMed ID: 11149048
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.